Gates Foundation directs $1.6B to Gavi, the Vaccine Alliance
The Bill and Melinda Gates Foundation announced a five-year, $1.6 billion U.S. commitment to Gavi, the Vaccine Alliance, to deliver vaccines to developing countries. The announcement was made at the Global Vaccine Summit 2020 on June 4. Read More
ImmunoPrecise, NIH, Integrated Biotherapeutics test antibodies for COVID-19
ImmunoPrecise Antibodies announced that it is collaborating with the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health (NIH) and Integrated Biotherapeutics to study molecular binding interactions of therapeutic antibody candidates for COVID-19. Read More
Intravacc forms public-private partnership for intranasal COVID-19 vaccine
Intravacc announced that it is partnering with Wageningen Bioveterinary Research and Utrecht University for the development of an intranasal vaccine against COVID-19. The public-private partnership will combine Intravacc viral vector technologies with animal technologies from Wageningen Bioveterinary Research and coronavirus expertise from Utrecht. Read More
Study reveals genomic similarity between SARS-CoV and SARS-CoV-2
A new technique has shown that conserved genetic sequences between SARS-CoV and SARS-CoV-2 may be important for their stability within host cells and ability to infect and replicate efficiently. The methodology was published in Biochemical and Biophysical Research Communications. Read More
AGC to manufacture adjuvant for Novavax COVID-19 vaccine
AGC Biologics announced it is partnering with Novavax for large-scale good manufacturing practices production of critical components for Novavax's coronavirus vaccine candidate, NVX-CoV2373. Read More
Dog tests positive for coronavirus, in 1st confirmed U.S. report
The National Veterinary Services Laboratories of the U.S. Department of Agriculture announced the first confirmed case of SARS-CoV-2 in a dog. Read More
Reverse genetics allows researchers to map SARS-CoV-2 in the body
A new study has revealed that SARS-CoV-2 infects the nasal cavity to the greatest degree and infects and replicates progressively less well in cells lower in the respiratory tract. The work, including the development of key laboratory tools, has been accepted by Cell. Read More
Intravacc, EpiVax partner for COVID-19 vaccine
Intravacc and EpiVax have entered a collaborative agreement to further develop a novel vaccine against COVID-19 based on Intravacc's proprietary outer membrane vesicle technology platform. Read More
Multiple recombination events may have led to SARS-CoV-2 in humans
A team of scientists evaluating how SARS-CoV-2 jumped to humans found that several genetic recombination events made it especially well-suited to infect humans, according to a study published in Science Advances on May 29. Read More
Lilly begins COVID-19 antibody treatment clinical trials
Eli Lilly announced that the first patients have been dosed with its lead COVID-19 antibody treatment candidate, LY-CoV555, according to the firm. The drug is a potent, neutralizing IgG1 monoclonal antibody directed against the spike protein of SARS-CoV-2. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter